Chemical Proteomic Analysis of Serine Hydrolase Activity in Niemann-Pick Type C Mouse Brain by Rooden, E.J. van et al.
fnins-12-00440 June 30, 2018 Time: 16:13 # 1
ORIGINAL RESEARCH











University of Tartu, Estonia
*Correspondence:
Mario van der Stelt
m.van.der.stelt@chem.leidenuniv.nl
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Neuroscience
Received: 19 February 2018
Accepted: 11 June 2018
Published: 03 July 2018
Citation:
van Rooden EJ, van Esbroeck ACM,
Baggelaar MP, Deng H, Florea BI,
Marques ARA, Ottenhoff R, Boot RG,
Overkleeft HS, Aerts JMFG and
van der Stelt M (2018) Chemical
Proteomic Analysis of Serine
Hydrolase Activity in Niemann-Pick
Type C Mouse Brain.
Front. Neurosci. 12:440.
doi: 10.3389/fnins.2018.00440
Chemical Proteomic Analysis of
Serine Hydrolase Activity in
Niemann-Pick Type C Mouse Brain
Eva J. van Rooden1, Annelot C. M. van Esbroeck1, Marc P. Baggelaar1, Hui Deng1,
Bogdan I. Florea2, André R. A. Marques3, Roelof Ottenhoff4, Rolf G. Boot5,
Herman S. Overkleeft2, Johannes M. F. G. Aerts5 and Mario van der Stelt1*
1 Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands, 2 Bioorganic Synthesis, Leiden
Institute of Chemistry, Leiden University, Leiden, Netherlands, 3 Institute of Biochemistry, Christian-Albrechts-Universität zu
Kiel, Kiel, Germany, 4 Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam,
Netherlands, 5 Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
The endocannabinoid system (ECS) is considered to be an endogenous protective
system in various neurodegenerative diseases. Niemann-Pick type C (NPC) is a
neurodegenerative disease in which the role of the ECS has not been studied yet.
Most of the endocannabinoid enzymes are serine hydrolases, which can be studied
using activity-based protein profiling (ABPP). Here, we report the serine hydrolase
activity in brain proteomes of a NPC mouse model as measured by ABPP. Two ABPP
methods are used: a gel-based method and a chemical proteomics method. The
activities of the following endocannabinoid enzymes were quantified: diacylglycerol
lipase (DAGL) α, α/β-hydrolase domain-containing protein 4, α/β-hydrolase domain-
containing protein 6, α/β-hydrolase domain-containing protein 12, fatty acid amide
hydrolase, and monoacylglycerol lipase. Using the gel-based method, two bands
were observed for DAGL α. Only the upper band corresponding to this enzyme was
significantly decreased in the NPC mouse model. Chemical proteomics showed that
three lysosomal serine hydrolase activities (retinoid-inducible serine carboxypeptidase,
cathepsin A, and palmitoyl-protein thioesterase 1) were increased in Niemann-Pick C1
protein knockout mouse brain compared to wild-type brain, whereas no difference
in endocannabinoid hydrolase activity was observed. We conclude that these targets
might be interesting therapeutic targets for future validation studies.
Keywords: chemical proteomics, activity-based protein profiling, endocannabinoid system, hydrolases,
Niemann-Pick type C
INTRODUCTION
The endocannabinoid system (ECS) consists of the cannabinoid type 1 and 2 receptors (CB1R
and CB2R) and their endogenous ligands: the endocannabinoids. The lipids anandamide (AEA)
and 2-arachidonoylglycerol (2-AG) are the best characterized endocannabinoids (Di Marzo
et al., 2004). The enzymes responsible for endocannabinoid biosynthesis and degradation are
Abbreviations: ABHD, α/β-hydrolase domain-containing protein; ABPP, activity-based protein profiling; AEA,
anandamide; 2-AG, 2-arachidonoylglycerol; CBxR, cannabinoid type x receptor; CTSA, cathepsin A; DAGL, diacylglycerol
lipase; ECS, endocannabinoid system; FAAH, fatty acid amide hydrolase; FP, fluorophosphonate; GBA2, non-lysosomal
glucosylceramidase; MAGL, monoacylglycerol lipase; NAPE, N-acylphospatidylethanolamine; NPC, Niemann-Pick type
C; PLA2G4E, phospholipase A2 group 4E; PLD, phospholipase D; PPT1, palmitoyl-protein thioesterase 1; SCPEP1,
retinoid-inducible serine carboxypeptidase; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; THL,
tetrahydrolipstatin.
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also part of the ECS, with most endocannabinoid degrading
enzymes belonging to the serine hydrolase family (Figure 1;
Blankman and Cravatt, 2013). The combined activities of
biosynthetic enzymes and degradative enzymes tightly regulate
endocannabinoid concentrations in the brain. For example,
2-AG is mainly produced from 1-acyl-2-AG by the diacylglycerol
lipases (DAGLs), DAGLα and DAGLβ, while it is degraded
by monoacylglycerol lipase (MAGL) and to a minor extent
by α,β-hydrolase domain-containing protein 6 (ABHD6)
and α,β-hydrolase domain-containing protein 12 (ABHD12).
Multiple pathways are known for the biosynthesis of AEA, but
they all use N-acylphospatidylethanolamine (NAPE) as a central
precursor, including the serine hydrolase α,β-hydrolase domain-
containing protein 4 (ABHD4) and the β-metallolactamase
N-acylphospatidylethanolamine-phospholipase D (NAPE-PLD).
NAPE is synthesized by the calcium-dependent N-acyltransferase
phospholipase A2 group 4E (PLA2G4E) (Ogura et al., 2016).
Fatty acid amide hydrolase (FAAH) terminates AEA signaling by
hydrolysis of its amide bond.
Endocannabinoid hydrolases that are part of the serine
hydrolase superfamily can be studied using activity-based protein
profiling (ABPP), a method which uses chemical probes for
measuring enzyme activity in complex biological samples.
Previously, we have used ABPP to compare serine hydrolase
activity in wild-type and CB1R knockout mice (Baggelaar et al.,
2017). Comparative ABPP has also been successfully applied
in the identification of new drug targets (Nomura et al.,
2010a,b). With ABPP, enzyme activities that are deregulated
in a certain pathophysiological state can be identified and
the relative amount of active enzyme copies as compared to
wild-type situations quantified. The classical fluorophosphonate
(FP)-based probes (FP-TAMRA and FP-biotin; Liu et al., 1999)
act as broad-spectrum serine hydrolase probes that label the
endocannabinoid enzymes FAAH, MAGL, PLA2G4E (Ogura
et al., 2016), ABHD6, and ABHD4 (Liu et al., 1999; Simon
and Cravatt, 2010), whereas the tailor-made tetrahydrolipstatin
(THL)-based probes (MB064 and MB108) label both DAGL
isoforms (alpha and beta) and ABHD4, ABHD6, and ABHD12
(Baggelaar et al., 2013, 2015, 2017; Ogasawara et al., 2016).
Of note, the fluorescent probe DH379 (Ogasawara et al.,
2016) selectively targets DAGL and ABHD6 (Supplementary
Figure S1).
Evaluation of endocannabinoid hydrolase activity in native
tissue may provide insight in the role of the ECS in physiological
and disease processes. Interestingly, endocannabinoid levels
are elevated during neurodegeneration and neuroinflammation
(van der Stelt and Di Marzo, 2005; Nomura et al., 2011;
Chiurchiù et al., 2017). For example, endocannabinoid signaling
is perturbed in various animal models of neurodegenerative
diseases, including stroke (Hillard, 2008), traumatic brain injury
(Schurman and Lichtman, 2017), Alzheimer’s disease (Bisogno
and Di Marzo, 2008), Huntington’s disease (Maccarrone et al.,
2007), Parkinson’s disease (Di Marzo et al., 2000; Maccarrone
et al., 2003), and multiple sclerosis (Baker et al., 2000). It
is hypothesized that regulation of ECS activity may provide
therapeutic benefit for these types of neurological diseases
(Scotter et al., 2010).
Niemann-Pick type C (NPC) is a neurodegenerative lysosomal
storage disorder, which is associated with mutations in either
of the genes encoding Niemann-Pick C1 protein (NPC1) or
NPC2 (Vanier and Millat, 2003). Both genes encode lysosomal
proteins that are sequentially involved in cholesterol transport
out of the lysosomes via a so far unknown mechanism. Defects
in the function of the soluble NPC2 or the lysosomal membrane
protein NPC1 leads to primary accumulation of cholesterol
and secondary storage of sphingomyelin, sphingosine, and
glycosphingolipids in lysosomes of multiple cell types, thereby
leading to visceral complications such as enlarged liver and
spleen combined with progressive neurological disease (Vanier
and Millat, 2003).
A NPC mouse model is available. These NPC mice
have previously been studied using ABPP with a retaining
β-glucosidase probe (Marques et al., 2015). This study showed
increased activity of the non-lysosomal glucosylceramidase
(GBA2) in NPC1 knockout mice (and consistent increased
abundance of the protein by Western blot). Importantly,
pharmacological inhibition of GBA2 ameliorated the
neuropathology of these mice (Marques et al., 2015). Miglustat
is approved as a drug, and initially thought to work through
substrate reduction by inhibiting glucosylceramide synthase
(Nietupski et al., 2012). However, as we have shown before,
the molecular mechanism does not involve glucosylceramide
synthase, and we hypothesized that the therapeutic effect seems
at least partly due to off-target inhibition of Miglustat on GBA2
(Marques et al., 2015). It has been suggested that accumulation of
sterols in lysosomes impaired in NPC1 (or NPC2) causes a more
general lysosome dysfunction involving multiple hydrolases,
such as lysosomal glucocerebrosidase (GBA; Ferraz et al., 2016).
Additionally, mutations in NPC1 or NPC2 genes result in severe
progressive neurodegeneration. These observations led us to
hypothesize that the hydrolases of the ECS might play a role in
this disease. There is no treatment available for NPC patients.
Additionally, there is no information available about the status
of the ECS in Niemann-Pick. Therefore, we set out to measure




Npc1−/− mice, along with wild-type littermates (Npc1+/+),
were generated as published previously (Marques et al., 2015).
Briefly, the heterozygous BALB/c Nctr-Npc1m1N/J mice (stock
number 003092) were obtained from The Jackson Laboratory
(Bar Harbor, ME, United States). The mice used in the current
study were crossed for six generations in c57/bl6 background.
Mouse pups were genotyped according to published protocols
(Loftus et al., 1997). The mice were housed at the Institute
Animal Core Facility in a temperature- and humidity-controlled
room with a 12-h light/dark cycle and given free access to food
and water ad libitum. All animal protocols were approved by
the Institutional Animal Welfare Committee of the Academic
Medical Centre Amsterdam in Netherlands. At the age of
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FIGURE 1 | Pathways for the biosynthesis and degradation of the endocannabinoids 2-AG and AEA. Enzymes with known activity-based probes are underlined.
R1/R2, alkyl chains, R3, arachidonoyl. ABHD, α/β-hydrolase domain-containing protein; AEA, anandamide; 2-AG: 2-arachidonoylglycerol; DAG, diacylglycerol;
DAGL, diacylglycerol lipase; FAAH, fatty acid amide hydrolase; GDE1, glycerophosphodiesterase 1; LPC, lysophosphatidylcholine; MAGL, monoacylglycerol lipase;
NAPE, N-acylphosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PIP2, phosphatidylinositol 4,5-bisphosphate; PLA2G4E,
phospholipase A2 group 4E; PLC, phospholipase C; PLD, phospholipase D.
69 days, animals were first anesthetized with a dose of Hypnorm
(0.315 mg/mL fenyl citrate and 10 mg/mL fluanisone) and
Dormicum (5 mg/mL midazolam) according to their weight. The
given dose was 80 µL/10 g body weight. Blood was collected
by a heart puncture followed by cervical dislocation. Brains
were dissected, rinsed with phosphate-buffered saline (PBS), snap
frozen in liquid N2, and stored at −80◦C for biochemistry. Brain
tissue was obtained from six female mice, three wildtype and
three knockout.
Preparation of Mouse Tissue Proteome
The mouse brains were cut in half with a scalpel through the
midsection (sagittal plane). The mouse brain halves were slowly
thawed on ice. The thawed mouse brain halves were dounce
homogenized in 1.5-mL cold (4◦C) lysis buffer (20 mM HEPES
pH 7.2, 2 mM DTT, 1 mM MgCl2, 25 U/mL benzonase) and
incubated for 15 min on ice. The suspension was centrifuged
(2500 g, 3 min, 4◦C) to remove debris. The supernatant
was collected and transferred to an ultracentrifuge tube. The
debris was resuspended in 0.25-mL lysis buffer and resubjected
to centrifugation. The combined supernatants were collected
and subjected to ultracentrifugation (100,000 g, 45 min, 4◦C,
Beckman Coulter, Type Ti70 rotor). This yielded the membrane
fraction as a pellet and the cytosolic fraction in the supernatant.
The supernatant was collected and the membrane fraction was
suspended in 1.5-mL storage buffer (20 mM HEPES pH 7.2,
2 mM DTT). The total protein concentration was determined
with Quick Start Bradford assay (Bio-Rad). Membranes and
supernatant fractions were both diluted to either 1.0 or
2.0 mg/mL (for proteomics and gel-based ABPP, respectively) and
were used directly or flash frozen in liquid nitrogen and stored in
aliquots at−80◦C until use.
Activity-Based Protein Profiling
Gel-Based
Mouse brain cytosol or membrane fraction (2.0 mg/mL) was
incubated with activity-based probe MB064 (250 nM), TAMRA-
FP (500 nM), or DH379 (1 µM) (20 min, rt, 2.5% DMSO). For
Frontiers in Neuroscience | www.frontiersin.org 3 July 2018 | Volume 12 | Article 440
fnins-12-00440 June 30, 2018 Time: 16:13 # 4
van Rooden et al. Chemical Proteomics of NPC Mouse
the competition experiments with inhibitor DH376, this step
was preceded by incubation with 100 nM inhibitor (30 min,
rt, 2.5% DMSO). For the competition experiments with probe
MB108, this step was preceded by incubation with 10 µM probe
(30 min, 37◦C, 2.5% DMSO). Laemmli buffer was added to
quench the protein activity and the mixture was allowed to
stand at rt for at least 5 min before the samples were loaded
and resolved on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel (10% acrylamide), together with
PageRuler Plus Prestained Protein Ladder (Thermo Scientific).
The gels were scanned using a ChemiDoc (Bio-Rad, Cy3 channel:
expose 180 s for MB064, 60 s for DH379/TAMRA-FP, Cy5
channel 10 s for marker). After fluorescent scanning, the gels
were stained with a Coomassie staining solution [0.25% (w/v)
Coomassie Brilliant Blue in 50% MeOH, 10% AcOH, 40% MilliQ
(v/v/v)]. The gels were scanned after destaining with MilliQ.
Both the fluorescence and Coomassie images were analyzed using
Image Lab 5.2. The Coomassie gel is used to determine protein
loading (automatic lane/band detection, background subtraction
not enabled, select whole lane as band). The fluorescence
bands are quantified using automatic lane/band detection with
background subtraction enabled. Using the Coomassie-corrected
gel fluorescence values, the average is calculated for WT and KO
and a two-sided Student’s t-test is performed. The activities of
proteins were relatively quantified by setting the average WT at
100%.
Western Blot
After the SDS-PAGE gel was resolved and imaged, proteins were
transferred to 0.2-µm polyvinylidene difluoride membranes with
a Trans-Blot TurboTM Transfer system (Bio-Rad). Membranes
were washed with TBS (50 mM Tris, 150 mM NaCl) and blocked
with 5% milk (w/v, Elk magere melkpoeder, FrieslandCampina)
in TBST (50 mM Tris, 150 mM NaCl, 0.05% Tween 20) for 1 h at
rt. Membranes were then incubated with the primary antibody
anti-DAGLα (1:1000, Cell Signaling Technology, #13626) in
5% BSA (w/v) in TBST (o/n, 4◦C), washed with TBST,
incubated with matching secondary antibody HRP-coupled-goat-
anti-rabbit (1:5000, Santa Cruz, sc2030) in 5% milk in TBST
(1 h, rt) and washed with TBST and TBS. Imaging solution
(10 mL Luminol, 100 µL ECL enhancer, 3 µL H2O2) was added
to develop membranes and chemiluminescence was detected
on the ChemiDoc (Bio-Rad) using standard chemiluminescence
settings. The signal was normalized to Coomassie staining and
quantified with Image Lab 5.2.
Proteomics
Mouse brain membrane or soluble proteome (245 µL,
1.0 mg/mL) was incubated with 5 µL 0.5 mM MB108
(10 µM) or FP-Biotin (10 µM) for 1 h at rt. The labeling
reaction was quenched and excess probe was removed by
chloroform/methanol precipitation: 250 µL MilliQ, 666 µL
MeOH, 166 µL CHCl3, and 150 µL MilliQ added subsequently
to each sample with a brief vortex after each addition. After
centrifugation (4000 rpm, 10 min), the top and bottom layer
surrounding the floating protein pellet was removed. 600 µL
MeOH was added and the pellet was resuspended by sonication
with a probe sonicator (10 s, 30% amplitude). After centrifugation
(14,000 rpm, 5 min), the methanol was removed and the protein
pellet was redissolved in 250 µL 6 M urea/25 mM ammonium
bicarbonate and allowed to incubate for 15 min. 2.5 µL 1 M
DTT was added and the mixture was heated to 65◦C for 15 min.
The sample was allowed to cool to rt (∼5 min) before 20 µL
0.5 M iodoacetamide was added and the sample was alkylated for
30 min in the dark. 70 µL 10% (wt/vol) SDS was added and the
proteome was heated for 5 min at 65◦C. The sample was diluted
with 2 mL PBS. 50 µL of 50% slurry of Avidin-Agarose from egg
white (Sigma-Aldrich) was washed with PBS and added to the
proteome sample in 1 mL PBS. The beads were incubated with
the proteome for 3 h, while rotating. The beads were isolated by
centrifugation (2500 g, 2 min) and washed with 0.5% (wt/vol)
SDS in PBS (1×) and PBS (3×). The proteins were digested
overnight with 500 ng sequencing grade trypsin (Promega) in
250 µL on-bead digestion buffer (100 mM Tris pH 8, 100 mM
NaCl, 1 mM CaCl2, 2% ACN) at 37◦C with vigorous shaking.
The pH was adjusted with formic acid to pH 3 and the beads
were removed. The peptides were isotopically labeled by on-stage
tip dimethyl labeling. Wild-type and knockout samples were
differently labeled with isotopic dimethyl labeling and combined
after labeling to allow comparison (wild-type light and knockout
heavy).
On-Stage Tip Dimethyl Labeling
The stage tips were made by inserting C18 material in a 200-
µL pipet tip. The step-wise procedure given in the Table 1
was followed for stage tip desalting and dimethyl labeling. The
solutions were eluted by centrifugal force and the constitutions
of the reagents are given below. For label-free quantification
samples, steps 6 and 7 are omitted.
Stage tip solution A is 0.5% (vol/vol) FA in H2O. Stage
tip solution B is 0.5% (vol/vol) FA in 80% (vol/vol) ACN in
H2O. Dimethyl labeling reagents: phosphate buffer (50 mM;
pH 7.5) with NaBH3CN 0.03 M containing either 2% (vol/vol)
CH2O (Light) or CD2O (Medium). After the final elution
step, the desired heavy and light samples were combined and
concentrated on a Speedvac to remove the ACN. The residue was
reconstituted in 95/3/0.1 H2O/ACN/FA (vol/vol) before LC/MS
analysis. Tryptic peptides were measured either on an Orbitrap
or Synapt mass spectrometer.
Orbitrap
Tryptic peptides were analyzed on a Surveyor nanoLC system
(Thermo) hyphenated to a LTQ-Orbitrap mass spectrometer
(Thermo) as previously described. Briefly, emitter, trap
and analytical column (C18, 120Å) were purchased from
Nanoseparations (Nieuwkoop, Netherlands) and mobile phases
(A: 0.1% formic acid/H2O, B: 0.1% formic acid/ACN) were
made with ULC/MS grade solvents (Biosolve). General mass
spectrometric conditions were: electrospray voltage of 1.8–
2.5 kV, no sheath and auxiliary gas flow, capillary voltage 40 V,
tube lens voltage 155 V, and ion transfer tube temperature
150◦C. Polydimethylcyclosiloxane (m/z = 445.12002) and dioctyl
phthalate ions (m/z = 391.28429) from the environment were
used as lock mass. Some 10 µL of the samples was pressure
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TABLE 1 | Step-wise on-stage tip dimethyl labeling procedure.
Step Aim Solution Centrifugation
1 Conditioning Methanol (50 µL) 2 min 600 g
2 Conditioning Stage tip solution B (50 µL) 2 min 600 g
3 Conditioning Stage tip solution A (50 µL) 2 min 600 g
4 Loading Load samples on stage tips 2.5 min 800 g
5 Washing Stage tip solution A (100 µL) 2.5 min 800 g
6 Dimethyl labeling (5×) 20/20/40/40/30 µL L or M reagent 5 min 400 g
7 Washing Stage tip solution A (100 µL) 2.5 min 800 g
8 Elution Stage tip solution B (100 µL) 2.5 min 800 g
loaded on the trap column for 5 min with a 10-µL/min flow and
separated with a gradient of 35 min 5–30% B, 15 min 30–60%
B, and 5 min A at a flow of 300 µL/min split to 250 nL/min by
the LTQ divert valve. Full MS scans (300–2000 m/z) acquired
at high mass resolution (60,000 at 400 m/z, maximum injection
time 1000 ms, AGC 106) in the Orbitrap was followed by three
MS/MS fragmentations in the LTQ linear ion trap (AGC 5× 103,
max inj time 120 ms) from the three most abundant ions.
MS/MS settings were: collision gas pressure 1.3 mT, normalized
collision energy 35%, ion selection threshold of 750 counts,
activation q = 0.25, and activation time 30 ms. Ions of z < 2
or unassigned were not analyzed and fragmented precursor
ions were measured twice within 10 s and were dynamically
excluded for 60 s. Data analysis was performed using Maxquant
with acetylation (protein N term) and oxidation (M) as variable
modifications. The false discovery rate was set at 1%, and
the peptides were screened against reviewed mouse proteome
(Uniprot). Serine hydrolases that were identified in at least two
repetitive experiments and for which at least one unique peptide
and two peptides in total were identified were considered as
valid quantifiable hits. For proteins identified by both probes,
the normalized ratios from Maxquant were combined for further
analysis. The binary logarithm of each ratio was compared to 0
with a Student’s t-test. The resulting p values were subjected to a
Benjamini–Hochberg correction, setting the false discovery rate
at 10% (q = 0.1). Briefly, the p values of all quantifiable hits were
ordered from lowest to highest, and the Benjamini–Hochberg
statistic was calculated as q × (position in the list) divided by
the number of tests. Subsequently, the proteins for which the p
value is smaller than the BH statistic are controlled for a FDR of
q× 10%.
Synapt
The peptides were measured as described previously for the
NanoACQUITY UPLC System coupled to SYNAPT G2-Si high
definition mass spectrometer. A trap-elute protocol, where 1 µL
of the digest is loaded on a trap column (C18 100Å, 5 µM,
180 µM× 20 mm, Waters) followed by elution and separation on
the analytical column (HSS-T3 C18 1.8 µM, 75 µM × 250 mm,
Waters). The sample is brought onto this column at a flow rate
of 10 µL/min with 99.5% solvent A for 2 min before switching
to the analytical column. Peptide separation is achieved using
a multistep concave gradient based on the gradients used in
Distler et al. (2016). The column is re-equilibrated to initial
conditions after washing with 90% solvent B. The rear seals of the
pump are flushed every 30 min with 10% (vol/vol) ACN. [Glu1]-
fibrinopeptide B (GluFib) is used as a lock mass compound.
The auxiliary pump of the LC system is used to deliver this
peptide to the reference sprayer (0.2 µL/min). A UDMSe method
is set up as described in Distler et al. (2016). Briefly, the mass
range is set from 50 to 2,000 Da with a scan time of 0.6 s in
positive, resolution mode. The collision energy is set to 4 V in
the trap cell for low energy MS mode. For the elevated energy
scan, the transfer cell collision energy is ramped using drift time
specific collision energies (Distler et al., 2014). The lock mass is
sampled every 30 s. Raw data are processed in PLGS (v3.0.3) and
ISOQuant v1.5.
RESULTS
In 95% of the patients afflicted by NPC, mutations in NPC1
are observed. Therefore, the role of the ECS in this disease
was investigated by comparison of endocannabinoid hydrolase
activity between Npc1+/+ and Npc1−/− mouse brains. First,
labeling profiles of MB064, DH379, and FP-TAMRA in wild-
type and knockout mouse brains was evaluated (Figure 2A).
Membrane and soluble fractions of both wild-type and knockout
tissue were labeled with each probe separately, resolved on
SDS-PAGE and visualized using in gel fluorescence scanning.
Coomassie staining was used as a protein loading control. The
fluorescence intensity of the bands corresponding to DAGLα
(∼120 kDa), ABHD12 (∼50 kDa), ABHD6 (∼35 kDa), and
FAAH (∼60 kDa) were quantified to determine the relative
enzyme activity between knockout and wildtype (Figure 2B).
Using the FP-TAMRA probe, the two bands corresponding to
MAGL (∼35 kDa) were observed, but due to band overlap
with ABHD6 these cannot be accurately quantified. Labeling
of DAGLα significantly decreased in the knockout mice as
compared to wildtype, while ABHD6 and ABHD12 activity was
the same. FAAH labeling was slightly decreased in the knockout,
but this decrease was not statistically significant. In the cytosolic
fraction, an increase in intensity of a 75-kDa band as labeled by
MB064 and FP-TAMRA was observed in the knockout brains.
As reported previously (Gao et al., 2010; Baggelaar et al., 2017),
DAGLα is identified as two separate bands. Remarkably, only the
fluorescent band corresponding to the higher molecular weight
was significantly decreased in the Npc1−/− mice as quantified
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FIGURE 2 | Gel-based Npc1+/+ (WT) vs. Npc1−/− (KO) comparison. (A) Enzyme activity in the brain fractions as measured by the probes MB064, DH379, and
FP-TAMRA. (B) Quantification of relative enzyme activity in WT and KO for probe targets (average WT is set to 100%). n = 3 (mice), n = 2 (MB064), or n = 1 (DH379
and FP-TAMRA). (C) Quantification of probe labeling of the two observed bands for DAGLα as measured by MB064 and DH379 [gels: (A)]. Three mice per condition
(N = 3) and three probe labeling experiments per lysate (n = 3). (D) DAGLα activity and abundance in DAGLα WT and KO mouse brain membrane proteome as
measured by the probe MB064 and an anti-DAGLα antibody. (E) DAGLα abundance in NPC1 WT and KO mouse brain membrane proteome. (F) Quantification of
antibody labeling of the two observed bands for DAGLα as measured by anti-DAGLα [blot: (E)]. Mean ± standard deviation is shown. ∗p < 0.05 (Student’s t-test).
by two separate probes MB064 and DH379 (Figure 2C). Both
bands can be labeled with a DAGLα antibody and are absent in
DAGLα KO mice (Figure 2D). To see if this observation was
due to a decrease of protein abundance, a Western blot against
DAGLα was performed (Figure 2E). The signal of antibody
labeling was quantified (Figure 2F). The same pattern was
observed for relative abundance as for relative activity: only the
upper band corresponding to DAGLα is significantly decreased
(Figures 2C,F).
Although several endocannabinoid enzymes can be quantified
with gel-based ABPP, multiple bands remain unidentified
(Figure 2A). Additional enzymes can be identified using a
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FIGURE 3 | Chemical proteomics comparison of Npc1+/+ (WT) vs. Npc1−/− (KO). Log2 ratio of enzyme activity in Npc1−/− brain proteome compared to Npc1+/+.
Activity was measured using FP-biotin or MB108 (both 10 µM). The data from both probes were combined for both the cytosolic and membrane fraction. The mean
and standard deviation are shown. Endocannabinoid related enzymes are underlined. Statistical analysis by means of Student’s t-test (each ratio was compared to a
log2 ratio of 0) and the resulting p values were subjected to Benjamini–Hochberg correction, setting the false discovery rate at 10% (∗ indicates significant difference).
sensitive mass spectrometry-based method for ABPP (chemical
proteomics). Therefore, to study a broader range of serine
hydrolases and to confirm our observations from the gel-
based assay, we also employed a chemical proteomics method
using FP biotin and MB108 to assess the role of the ECS
in NPC1. The enzymatic activity of 41 hydrolases in NPC1
knockout mouse brain were identified and compared with
wild-type mouse brains (Figure 3). In line with the gel-
based ABPP, we did not find any significant difference in
the endocannabinoid hydrolase activity (ABHD12, ABHD6,
FAAH, and MAGL) in NPC1 wild-type vs. knockout mice brain
proteomes. The activity of endocannabinoid hydrolase ABHD4
is also unaltered in knockout compared to wildtype. Remarkably,
and in contrast to the gel-based ABPP results, DAGLα
activity in knockout mice brain proteomes was not decreased
compared to wild-type mice. Of note, in a control experiment,
biotinylated probe MB108 competes with both DAGLα bands
labeled by the fluorescent probe MB064. Additionally, DAGL
inhibitor DH376 did reduce DAGLα labeling in the chemical
proteomics assay (Supplementary Figure S2). Finally, three
hydrolases were significantly increased in knockout mouse
brains compared to wild-type brains: retinoid-inducible serine
carboxypeptidase (SCPEP1), cathepsin A (CTSA), and palmitoyl-
protein thioesterase 1 (PPT1) (Figure 3).
DISCUSSION
We used ABPP to quantify the activity of the endocannabinoid
hydrolases FAAH, ABHD6, ABHD12, ABHD4, and MAGL in
NPC1 knockout mice and found that their activity is not
affected in wild-type vs. NPC1 knockout mice. DAGLα activity
seems to be decreased in the knockout mice based on the
gel-based ABPP results. However, we found a discrepancy in
the gel-based ABPP assay and the chemical proteomics assay
in DAGLα activity between the NPC1 knockout mouse brains
compared to wild-type mice. This discrepancy can possibly
be caused by technical factors inherent to the two applied
methodologies. In the gel-based ABPP assay, only the labeling
of the upper DAGLα-band was abolished in the NPC1 knockout
brain proteome. It could be that the peptides from the protein
corresponding to the upper band from the wild-type mouse
proteome are not detected in the mass spectrometer due to post-
translational modifications, such as phosphorylation, acetylation,
methylation, palmitoylation, or glycosylation. Peptides with such
modifications are not found in our assay. If this would be
true, a decrease in DAGLα activity in the NPC1 knockout
mice would not be detected. Further experiments, such as
direct quantification of 2-AG levels, are required to confirm a
decrease in DAGLα activity in Niemann-Pick mice. In addition,
it would be interesting to find the origin and role of the altered
modification of DAGLα in NPC. If the gel-based ABPP results
are confirmed, it would be worthwhile to measure 2-AG levels
and test the hypothesis that decreased DAGL activity might
represent a neuroprotective response by lowering the formation
of pro-inflammatory prostaglandins (Ogasawara et al., 2016).
Alternatively, it is known that 2-AG reduces cytotoxic edema
in traumatic brain injury (Panikashvili et al., 2001), therefore
boosting 2-AG brain levels by inhibition of MAGL may constitute
a neuroprotective response.
Finally, we found that the activities of three non-
endocannabinoid hydrolases, namely, CTSA, PPT1, and SCPEP1,
were significantly elevated in NPC1 knockout mouse brains.
These enzymes are lysosomal proteins, which is in line with the
important role of NPC1 in lysosomes. SCPEP1 shows homology
with CTSA (Kollmann et al., 2009) and a study with double
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knockout of SCPEP1 and CTSA suggests they share the same
peptide substrate (Pan et al., 2014). Single knockout of SCPEP1
in mice resulted in viable mice without lysosomal impairment
(Kollmann et al., 2009). Mutations in the CTSA gene cause
galactosialidosis in humans (Galjart et al., 1990) and secondary
deficiencies of beta-galactosidase and neuraminidase. This same
phenotype is mirrored in a CTSA knockout mice mouse model
(Korah et al., 2003). The protective role of the enzyme for
galactosidase and neuraminidase is a structural function of the
enzyme: mice with catalytic serine-to-alanine mutation have
normal levels of β-galactosidase and neuraminidase (Seyrantepe
et al., 2008). CTSA inhibitors have been tested in humans (Tillner
et al., 2016), and CTSA is a therapeutic target for the treatment
of cardiovascular diseases (Schreuder et al., 2014; Petrera et al.,
2016). Thus, it would be interesting to test CTSA inhibitors
in Niemann-Pick models. PPT1 is also a lysosomal enzyme
(Lu et al., 2002) and the dysregulation of this enzyme causes
a lysosomal storage and neurodegenerative disorder; infantile
neuronal ceroid lipofuscinosis (Tillner et al., 2016). This enzyme
removes palmitoyl modifications from proteins that are being
degraded in the lysosome. In PPT1 knockout mice, cholesterol
catabolism is altered (Ahtiainen et al., 2007). PPT1 has been
proposed to hydrolyze 2-AG and might therefore be involved in
the ECS (Wang et al., 2013). In vivo active inhibitors for PPT1
(Cognetta et al., 2015) have been identified and could therefore
also be tested in Niemann-Pick models. To conclude, we have
found no altered activity of endocannabinoid hydrolases in a
NPC mouse model using our chemical proteomics assay. Three
hydrolases were identified with upregulated activity in NPC1
knockout mice, which might be interesting therapeutic target for
future studies.
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